In silico analysis identified aminoglycosides as urease inhibitors in Helicobacter pylori, suggesting therapeutic potential.
Key Points
Aminoglycoside drugs effectively inhibit urease activity in Helicobacter pylori, showing promise in treating infections.
Molecular docking results reveal that paromomycin, tobramycin, gentamicin, amikacin, and capreomycin bind strongly to urease's active site.
In vitro studies demonstrate dose-dependent inhibition of urease activity, with significant differences observed at P ≤ 0.05 compared to reference strains.
The findings highlight a new potential approach for targeting Helicobacter pylori-related gastrointestinal diseases using aminoglycosides.